Episode Details
Back to Episodes
May 05, 2026 | Cytokinetics Cracks Non-Obstructive HCM; Pfizer's $2.3B Trillium Write-Off
Description
Myqorzo hits both endpoints in ACACIA-HCM, opening amultibillion-dollar HCM market Camzyos can't reach. Plus: Pfizer scraps its last CD47 program from the $2.3B Trillium acquisition, Madrigal licenses Arrowhead's PNPLA3 siRNA for up to $1B, and the Supreme Court keeps mifepristone in play.
Visit us at www.thepharamcloseout.com
pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Cytokinetics,Myqorzo, aficamten, hypertrophic cardiomyopathy, HCM, ACACIA-HCM, Pfizer,Trillium Therapeutics, CD47, Madrigal, Arrowhead, MASH, PNPLA3, Rezdiffra,mifepristone, Supreme Court, Auvelity, Axsome, Viridian, Tepezza, Intercept,BioNTech, Jakafi XR, Incyte, Leqembi, Sanofi, Passage Bio, Gilead, Arcellx,Novartis, J&J, Amgen